Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

162

Participants

Timeline

Start Date

February 28, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

November 30, 2025

Conditions

Type 2 Diabetes

Interventions

DRUG

DA5221-T1

DA5221-T1 + DA5221-R2, orally, once daily, up to 24 weeks

DRUG

DA5221-T2

DA5221-R1 + DA5221-T2, orally, once daily, up to 24 weeks

DRUG

Placebo

DA5221-R1 + DA5221-R2, orally, once daily, up to 24 weeks

DRUG

DA5221-B1

DA5221-B1, orally, daily for background therapy

DRUG

DA5221-B2

DA5221-B2, orally, daily for background therapy

Trial Locations (1)

Severance Hospital, Yonsei University college of Medicine, Seoul

All Listed Sponsors

lead

Dong-A ST Co., Ltd.

INDUSTRY